Current Clinical Application of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases of Non-Small Cell Lung Cancer
Xin Yao （ Department of the Second Clinical Medical College of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi,712046,China ）
Xiao-Long Yan （ Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, No. 1, Xinsi Road, Xi’an, Shaanxi,710038, China ）
https://doi.org/10.37155/3060-8708-0201-3Abstract
Brain metastasis is a common complication in patients with non-small cell lung cancer (NSCLC). The occurrence of brain metastases has become a challenging issue in the treatment and prognosis of NSCLC. Therefore, identifying the most appropriate therapeutic strategies for patients with brain metastases is essential for prolonging survival. Traditional surgical and radiotherapy approaches have shown limited efficacy, and the blood-brain barrier significantly hinders the penetration of chemotherapeutic agents into the brain. In recent years, immune checkpoint inhibitors (ICIs) have achieved remarkable progress in the treatment of NSCLC. Given that both ICIs and anti-angiogenic agents target the tumor microenvironment, existing evidence supports a synergistic antitumor effect when these agents are used in combination. Furthermore, molecular targeted therapies and ICIs have opened new avenues and treatment options for NSCLC patients with brain metastases. This article discusses the application of immunotherapy and anti-angiogenic agents in NSCLC brain metastases, providing updated therapeutic insights for affected patients.
Keywords
Non-small cell lung cancer; immune checkpoint inhibitors; anti-angiogenic agents; brain metastasesFull Text
PDFReferences
[1]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics, 2020[J].CA Cancer J Clin,2020,70（1）：7-30.
[2]SUNG H,FERLAY J,SIEGEL RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185Countries[J].CA: a Cancer Journal for Clinicians,2021,71（3）：209-249.
[3]Shi Yuankai, Sun Yan, Yu Jinming, et al. Chinese Expert Consensus on the Diagnosis and Treatment of Brain Metastases from Lung Cancer (2017 Version). Chinese Journal of Lung Cancer. 2017;20(1):1-13.
[4]Peters S,Bexelius C,Munk V,etal.The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-samall-cell lung cancer ,［ J］.Cancer Treat Rev,2016,45:139-116.
[5]Iuchi T,Shingyoji M,Itakura M,etal.Frequency ofbrain metastases in non-small-cell lung cancer,and their association with epidermal growthfactor receptor mutations［ J］. Int jclin oncol,2015,29(4):674-679
[6]DARVIN P,TOOR SM, SASIDHARAN NAIR V,et al. Immune checkpoint inhibitors: recent progress and potential biomarkers[J].Experimental & Molecular Medicine,2018,50（12）：1-11.
[7]ONOI K,CHIHARA Y,UCHINO J,et al.Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review[J]. Journal of Clinical Medicine,2020,9（5）：1362.
[8]Q8IANG H,CHANG Q,XU J,et al.New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer[J].Journal of Cancer Research and Clinical Oncology,2020,146 （3）：631-645.
[9]Arvanitis CD,Ferraro GB,Jain RK. The blood-brain barrier and blood-tumour barrier in brain
[10]Tumours and metastases[J].Nat REV Cancer,2020,20(1) :26-41.
[11]Kim SJ,Kim JS,Park ES,etal.Astrocytes upregulate survival genes in tumor cells and induce protection form chemotherapy [J].Neoplasia,2011,13(3):286-298
[12]Schvartsman G,Ferrarotto R,Massarelli E.Checkpoint inhibitors in lungcancer:latest developments andclinical potential[J].Ther Adv Med oncol,2016,8( 6):460-473.
[13]Crion L,Bronte G,Bidoli P,eral.Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer [J].Lung Cancer,2019,129:35-40.
[14]Garon EB,Hellmann MD,Rizvi NA,etal.Five-year over all survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab:results from the phase IKEYNOTE-001 atudy [J].J Clin Oncol,2019,37(28):2518-2527.
[15]Nosaki K,Saka H,Hosomo Y,etal.Safety and efficacy of pembrol-izumab monotherapy in elderly patients with PD-L1-positive ad-vanced non-small-cell lung cancer:pooled ananalysis from the KEYNOTE-010,KEYNOTE-024,and KEYNOTE-024,and KEYNOTE-042 studies [J].Lung Cancer,2019135:188-195.
[16]Martin AM,Cagney DN,Catalano PJ,etal.Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with sstereotactic radiation [J].JAMA Oncol,2018,4(8):1123-1124.
[17]Tian Y,Zhai x,Tian H,etal.Bevacizumab in combination with pemetrexed and platinum significantly improved the clinical out-come of patients with advanced adenocarcinoma NSCLC and brain metases [J].Cancer Manag Res,2019,11:10083-1009.
[18]Jiang T,Zhang Y,LIX,etal.EGFR-TKIs plus bevacizumab dem-onstrateed survival benefit than EGFR-TKIs alone in metastases [J].Eur J Cancer,2019,121:98-108.
[19]Han Baohui, Li Kai, Zhou Caicun, et al. Chinese Expert Consensus on Anti-angiogenic Therapy for Advanced Non-Small Cell Lung Cancer (2019 Edition). Chinese Journal of Lung Cancer. 2019;22(7):401–412.
[20]Jiang s,Liang H,Liu Z,etal.The impact of anlotinib on brain metastases of non-small-cell lung cancer:post hoc analysis of a phase IIIrandomized control trial (ALTER0303) [J] Oncologist,2020,25(5):e870-e874.
[21]Wu D,Nie j,Dai l,etal. Salvage treatment with anlotinib for ad-vanced non-small-cell ling canver [J].Th0rac Cancer,2019,10(7):1590-1596.
[22]Jiang X,Ding m,Qiao Y,etal. Recombination human denostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer [J].Clin Transl Oncol,2014,16(7):630-636.
[23]Zhao Yongli, Dong Jigang, Li Bo, et al. Value Analysis of the Optimal Time Window for Maximizing Blood-Brain Barrier Permeability in the Treatment of Multiple Brain Metastases from Non-Small Cell Lung Cancer. Modern Oncology. 2017;25(4):2238–2242.
[24]YI M,JIAO D,QIN S,et al.Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment[J].Molecular Cancer,2019,18 (1)：60.
[25]HUANG Y,KIM B,CHAN C K,et al.Improving immune-vascular crosstalk for cancer immunotherapy[J]. Nat Rev Immunol,2018,18（3）：195-203.
[26]KAMMERTOENS T,FRIESE C,ARINA A,et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression[J].Nature,2017, 545（7652）：98-102.
[27]TIAN L,GOLDSTEIN A,WANG H,et al.Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming[J].Nature,2017, 544（7649）：250-254
[28]FANG L,ZHAO W,YE B,et al.Combination ofImmune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer[J].Frontiers in Oncology,2021,11：670313.
[29]SONG Y,FU Y,XIE Q,et al.Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment[J]. Frontiers in Immunology,2020,11：1956.
[30]ALFARO C,SUAREZ N,GRANDE-PULIDO E,et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes[J].British Journal of Cancer,2009,100（7）： 1111-1119.
[31]AGGARWAL V,TULI H,VAROL A,et al.Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements[J]. Biomolecules,2019,（11）：735.
[32]MISSIAEN R,MAZZONE M,BERGERS G.The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer[J].Semin Cancer Biol,2018,52（Pt 2）:107-116.
[33]LIU Y,CAO X.Immunosuppressive cells in tumor immune escape and metastasis[J].Journal of Molecular Medicine,2016,94（5）：509-522.
[34]MARVEL D,GABRILOVICH DI.Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected[J].Journal of Clinical Investigation,2015,125（9）：3356-3364.
[35]De SANCTIS F,UGEL S,FACCIPONTE J,et al.The dark side of tumor-associated endothelial cells[J]. Seminars in Immunology,2018,35：35-47.
[36]ZHAO S,REN S,JIANG T,et al.Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer[J].Cancer Immunology Research,2019,7（4）:630-643.
[37]HackSP, ZhuAX,WangYL.Augmenting anticancer immunitythrough combined targeting of angiogenic and PD-1/PD-L1 pathways:challenges and opportunities［J］. Front Immunol, 2020,11：598877.
[38]JasziaJ, Schmidt MHH. Trends and challenges in tumor antiangiogenic therapies［J］. Cells,2019,8（9）： E1102.
[2]SUNG H,FERLAY J,SIEGEL RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185Countries[J].CA: a Cancer Journal for Clinicians,2021,71（3）：209-249.
[3]Shi Yuankai, Sun Yan, Yu Jinming, et al. Chinese Expert Consensus on the Diagnosis and Treatment of Brain Metastases from Lung Cancer (2017 Version). Chinese Journal of Lung Cancer. 2017;20(1):1-13.
[4]Peters S,Bexelius C,Munk V,etal.The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-samall-cell lung cancer ,［ J］.Cancer Treat Rev,2016,45:139-116.
[5]Iuchi T,Shingyoji M,Itakura M,etal.Frequency ofbrain metastases in non-small-cell lung cancer,and their association with epidermal growthfactor receptor mutations［ J］. Int jclin oncol,2015,29(4):674-679
[6]DARVIN P,TOOR SM, SASIDHARAN NAIR V,et al. Immune checkpoint inhibitors: recent progress and potential biomarkers[J].Experimental & Molecular Medicine,2018,50（12）：1-11.
[7]ONOI K,CHIHARA Y,UCHINO J,et al.Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review[J]. Journal of Clinical Medicine,2020,9（5）：1362.
[8]Q8IANG H,CHANG Q,XU J,et al.New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer[J].Journal of Cancer Research and Clinical Oncology,2020,146 （3）：631-645.
[9]Arvanitis CD,Ferraro GB,Jain RK. The blood-brain barrier and blood-tumour barrier in brain
[10]Tumours and metastases[J].Nat REV Cancer,2020,20(1) :26-41.
[11]Kim SJ,Kim JS,Park ES,etal.Astrocytes upregulate survival genes in tumor cells and induce protection form chemotherapy [J].Neoplasia,2011,13(3):286-298
[12]Schvartsman G,Ferrarotto R,Massarelli E.Checkpoint inhibitors in lungcancer:latest developments andclinical potential[J].Ther Adv Med oncol,2016,8( 6):460-473.
[13]Crion L,Bronte G,Bidoli P,eral.Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer [J].Lung Cancer,2019,129:35-40.
[14]Garon EB,Hellmann MD,Rizvi NA,etal.Five-year over all survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab:results from the phase IKEYNOTE-001 atudy [J].J Clin Oncol,2019,37(28):2518-2527.
[15]Nosaki K,Saka H,Hosomo Y,etal.Safety and efficacy of pembrol-izumab monotherapy in elderly patients with PD-L1-positive ad-vanced non-small-cell lung cancer:pooled ananalysis from the KEYNOTE-010,KEYNOTE-024,and KEYNOTE-024,and KEYNOTE-042 studies [J].Lung Cancer,2019135:188-195.
[16]Martin AM,Cagney DN,Catalano PJ,etal.Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with sstereotactic radiation [J].JAMA Oncol,2018,4(8):1123-1124.
[17]Tian Y,Zhai x,Tian H,etal.Bevacizumab in combination with pemetrexed and platinum significantly improved the clinical out-come of patients with advanced adenocarcinoma NSCLC and brain metases [J].Cancer Manag Res,2019,11:10083-1009.
[18]Jiang T,Zhang Y,LIX,etal.EGFR-TKIs plus bevacizumab dem-onstrateed survival benefit than EGFR-TKIs alone in metastases [J].Eur J Cancer,2019,121:98-108.
[19]Han Baohui, Li Kai, Zhou Caicun, et al. Chinese Expert Consensus on Anti-angiogenic Therapy for Advanced Non-Small Cell Lung Cancer (2019 Edition). Chinese Journal of Lung Cancer. 2019;22(7):401–412.
[20]Jiang s,Liang H,Liu Z,etal.The impact of anlotinib on brain metastases of non-small-cell lung cancer:post hoc analysis of a phase IIIrandomized control trial (ALTER0303) [J] Oncologist,2020,25(5):e870-e874.
[21]Wu D,Nie j,Dai l,etal. Salvage treatment with anlotinib for ad-vanced non-small-cell ling canver [J].Th0rac Cancer,2019,10(7):1590-1596.
[22]Jiang X,Ding m,Qiao Y,etal. Recombination human denostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer [J].Clin Transl Oncol,2014,16(7):630-636.
[23]Zhao Yongli, Dong Jigang, Li Bo, et al. Value Analysis of the Optimal Time Window for Maximizing Blood-Brain Barrier Permeability in the Treatment of Multiple Brain Metastases from Non-Small Cell Lung Cancer. Modern Oncology. 2017;25(4):2238–2242.
[24]YI M,JIAO D,QIN S,et al.Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment[J].Molecular Cancer,2019,18 (1)：60.
[25]HUANG Y,KIM B,CHAN C K,et al.Improving immune-vascular crosstalk for cancer immunotherapy[J]. Nat Rev Immunol,2018,18（3）：195-203.
[26]KAMMERTOENS T,FRIESE C,ARINA A,et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression[J].Nature,2017, 545（7652）：98-102.
[27]TIAN L,GOLDSTEIN A,WANG H,et al.Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming[J].Nature,2017, 544（7649）：250-254
[28]FANG L,ZHAO W,YE B,et al.Combination ofImmune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer[J].Frontiers in Oncology,2021,11：670313.
[29]SONG Y,FU Y,XIE Q,et al.Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment[J]. Frontiers in Immunology,2020,11：1956.
[30]ALFARO C,SUAREZ N,GRANDE-PULIDO E,et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes[J].British Journal of Cancer,2009,100（7）： 1111-1119.
[31]AGGARWAL V,TULI H,VAROL A,et al.Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements[J]. Biomolecules,2019,（11）：735.
[32]MISSIAEN R,MAZZONE M,BERGERS G.The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer[J].Semin Cancer Biol,2018,52（Pt 2）:107-116.
[33]LIU Y,CAO X.Immunosuppressive cells in tumor immune escape and metastasis[J].Journal of Molecular Medicine,2016,94（5）：509-522.
[34]MARVEL D,GABRILOVICH DI.Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected[J].Journal of Clinical Investigation,2015,125（9）：3356-3364.
[35]De SANCTIS F,UGEL S,FACCIPONTE J,et al.The dark side of tumor-associated endothelial cells[J]. Seminars in Immunology,2018,35：35-47.
[36]ZHAO S,REN S,JIANG T,et al.Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer[J].Cancer Immunology Research,2019,7（4）:630-643.
[37]HackSP, ZhuAX,WangYL.Augmenting anticancer immunitythrough combined targeting of angiogenic and PD-1/PD-L1 pathways:challenges and opportunities［J］. Front Immunol, 2020,11：598877.
[38]JasziaJ, Schmidt MHH. Trends and challenges in tumor antiangiogenic therapies［J］. Cells,2019,8（9）： E1102.
Copyright © 2025 Xin Yao,Xiao-Long Yan
Publishing time:2025-02-28
This work is licensed under a Creative Commons Attribution 4.0 International License
Email
Location